drugset / Trial / NCT03317899
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase 2
Completed
77 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma. Eliminating the use of tbo-filgrastim after transplant may still help maintain a similar time to discharge.
Timeline
- Start
- 2017-10-12
- Primary completion
- 2021-06-01
- Completion
- 2022-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | filgrastim | Protein / enzyme biologic | — | Subcutaneous |